786 related articles for article (PubMed ID: 28506759)
1. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
2. Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-hydroxylase and Inhibited by Some PHD Inhibitors.
Bhute VJ; Harte J; Houghton JW; Maxwell PH
Kidney360; 2020 Jun; 1(6):447-457. PubMed ID: 35368589
[TBL] [Abstract][Full Text] [Related]
3. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
[TBL] [Abstract][Full Text] [Related]
4. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Strowitzki MJ; Cummins EP; Taylor CT
Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
[TBL] [Abstract][Full Text] [Related]
5. Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
Flashman E; Davies SL; Yeoh KK; Schofield CJ
Biochem J; 2010 Mar; 427(1):135-42. PubMed ID: 20055761
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.
Kobayashi H; Liu J; Urrutia AA; Burmakin M; Ishii K; Rajan M; Davidoff O; Saifudeen Z; Haase VH
Kidney Int; 2017 Dec; 92(6):1370-1383. PubMed ID: 28847650
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Figg WD; Fiorini G; Chowdhury R; Nakashima Y; Tumber A; McDonough MA; Schofield CJ
Proteins; 2023 Nov; 91(11):1510-1524. PubMed ID: 37449559
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of hypoxia-inducible factor-prolyl hydroxylation protects from cyclophosphamide-induced bladder injury and urinary dysfunction.
Clayton DB; Tong CMC; Li B; Taylor AS; De S; Mason MD; Dudley AG; Davidoff O; Kobayashi H; Haase VH
Am J Physiol Renal Physiol; 2022 Jul; 323(1):F81-F91. PubMed ID: 35499237
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
10. Assays to Study Hypoxia-Inducible Factor Prolyl Hydroxylase Domain 2 (PHD2), a Key Human Oxygen Sensing Protein.
Chan YY; Mbenza NM; Chan MC; Leung IKH
Methods Mol Biol; 2023; 2648():187-206. PubMed ID: 37039992
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of a viral prolyl hydroxylase.
Langley GW; Abboud MI; Lohans CT; Schofield CJ
Bioorg Med Chem; 2019 Jun; 27(12):2405-2412. PubMed ID: 30737136
[TBL] [Abstract][Full Text] [Related]
12. Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions.
Floyd ZE; Kilroy G; Wu X; Gimble JM
J Cell Biochem; 2007 Aug; 101(6):1545-57. PubMed ID: 17370314
[TBL] [Abstract][Full Text] [Related]
13. Prolyl hydroxylases and therapeutics.
Smith TG; Talbot NP
Antioxid Redox Signal; 2010 Apr; 12(4):431-3. PubMed ID: 19761407
[TBL] [Abstract][Full Text] [Related]
14. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.
Berra E; Benizri E; Ginouvès A; Volmat V; Roux D; Pouysségur J
EMBO J; 2003 Aug; 22(16):4082-90. PubMed ID: 12912907
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases.
Chowdhury R; McDonough MA; Mecinović J; Loenarz C; Flashman E; Hewitson KS; Domene C; Schofield CJ
Structure; 2009 Jul; 17(7):981-9. PubMed ID: 19604478
[TBL] [Abstract][Full Text] [Related]
16. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
20. The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia.
Guo Z; Yang Y; Li L; Zhao Q; Li Y; Liu Z; Hao L; Guo B; Diao A
Eur J Pharmacol; 2022 Nov; 934():175307. PubMed ID: 36191632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
